BioSyent Stock

BioSyent EBIT

The EBIT of BioSyent (RX.V) as of Jul 21, 2026 is 9.06 M CAD. In the previous year, EBIT was 7.53 M CAD — a change of 20.31% (higher).

EBIT

9.06 MCAD

YoY

20.31%

Last updated:

In 2026, BioSyent's EBIT was 9.06 M CAD, a 20.31% increase from the 7.53 M CAD EBIT recorded in the previous year.

The BioSyent EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M CAD)
Date
EBIT (M CAD)
Jan 1, 2020
5.13 base
Jan 1, 2021
8.25 base
Jan 1, 2022
7.01 base
Jan 1, 2023
7.53 base
Jan 1, 2024
9.06 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
YEAREBIT (M CAD)
2027 est -
2026 est -
2025 est -
2024 9.06
2023 7.53
2022 7.01
2021 8.25
2020 5.13
2019 6.37
2018 6.75
2017 6.50
2016 5.77
2015 5.06
2014 4.10
2013 2.42
2012 1.38
2011 0.43
2010 0.06
2009 -0.28
2008 -0.31
2007 -0.13
2006 0.37
2005 -0.10
Access this data via the Eulerpool API

BioSyent Revenue

BioSyent Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
22.33 M CAD
5.13 M CAD
3.80 M CAD
Jan 1, 2021
28.62 M CAD
8.25 M CAD
6.28 M CAD
Jan 1, 2022
27.93 M CAD
7.01 M CAD
5.46 M CAD
Jan 1, 2023
31.59 M CAD
7.53 M CAD
6.46 M CAD
Jan 1, 2024
35.03 M CAD
9.06 M CAD
7.27 M CAD
Jan 1, 2025 (e)
44.47 M CAD
0.00 CAD
8.91 M CAD
Jan 1, 2026 (e)
45.80 M CAD
0.00 CAD
10.48 M CAD
Jan 1, 2027 (e)
49.47 M CAD
0.00 CAD
11.44 M CAD

BioSyent Margins

BioSyent stock margins

The BioSyent margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioSyent. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioSyent.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
78.02 %
22.95 %
16.99 %
Jan 1, 2021
79.10 %
28.82 %
21.95 %
Jan 1, 2022
81.85 %
25.11 %
19.55 %
Jan 1, 2023
81.03 %
23.85 %
20.45 %
Jan 1, 2024
79.52 %
25.88 %
20.75 %
Jan 1, 2025 (e)
79.52 %
0.00 %
20.04 %
Jan 1, 2026 (e)
79.52 %
0.00 %
22.88 %
Jan 1, 2027 (e)
79.52 %
0.00 %
23.13 %

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing BioSyent's EBIT

BioSyent's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of BioSyent's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

BioSyent's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in BioSyent’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about BioSyent stock

EBIT of BioSyent is 9.06 M CAD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — BioSyent

All Key Metrics — BioSyent